Patient Square Capital’s Kymera Therapeutics KYMR Stock Holding History

Patient Square Capital’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.45M	Sell	47,500 -52,500	-53%	-$4.51M	0.84%	22
2026 Q1	$8.33M	Sell	100,000 -39,000	-28%	-$3.09M	1.48%	19
2025 Q4	$10.8M	Buy	139,000 +46,408	+50%	+$3.13M	2.32%	12
2025 Q3	$5.24M	Sell	92,592 -47,408	-34%	-$2.14M	1.4%	12
2025 Q2	$6.11M	Sell	140,000 -2,201	-2%	-$75.8K	2.2%	8
2025 Q1	$3.89M	Buy	+142,201	New	+$5.18M	1.61%	13

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Patient Square Capital's KYMR Position: Q2 2026 in Review

Patient Square Capital reduced its Kymera Therapeutics (KYMR) stake by 53% in Q2 2026, selling an estimated $4.51M and leaving 47,500 shares worth $5.45M. The position accounts for 0.84% of the portfolio, ranked #22.

Patient Square Capital first reported a position in KYMR in Q1 2025 and has held it in 6 quarters since. The position peaked at $10.8M in Q4 2025. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

Patient Square Capital held 47,500 shares of Kymera Therapeutics worth $5.45M as of Q2 2026.
Patient Square Capital sold 52,500 Kymera Therapeutics shares in Q2 2026, an estimated $4.51M.
Kymera Therapeutics made up 0.84% of Patient Square Capital's portfolio in Q2 2026, its #22 holding.
Patient Square Capital first reported a position in Kymera Therapeutics in Q1 2025 and has held it in 6 quarters since.
Patient Square Capital's Kymera Therapeutics position peaked at $10.8M in Q4 2025.
276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Patient Square Capital's 13F filing for Q2 2026, filed 12 Aug 2026.